Jaundice — Breast Milk

Current guidelines from the American Academy of Pediatrics (AAP) recommend continuing breastfeeding. Phototherapy is reserved for cases where bilirubin levels cross the treatment threshold based on the infant’s age, gestational age, and risk factors (e.g., levels >15-18 mg/dL in a term infant over two weeks old). In extreme, rare cases (e.g., levels approaching exchange transfusion thresholds), temporary interruption of breastfeeding may be necessary, but the mother should continue pumping to maintain supply. For mild to moderate BMJ, frequent breastfeeding (to promote stooling) and outpatient follow-up are sufficient. Parental education is paramount; caregivers must be told that the yellow hue may persist for weeks but is not harming their baby, provided hydration and weight gain remain optimal.

Today, the focus has shifted to and, more notably, β-glucuronidase . Normally, conjugated bilirubin is excreted into the gut and eliminated in stool. However, β-glucuronidase—an enzyme present in high concentrations in some human milk—can deconjugate bilirubin in the infant’s gut, converting it back to its unconjugated (fat-soluble) form. This unconjugated bilirubin is then readily reabsorbed into the bloodstream via the enterohepatic circulation. High levels of β-glucuronidase in breast milk, combined with an immature neonatal gut flora, may create a cycle of reabsorption that prolongs jaundice. Genetic variations in the UGT1A1 gene (such as Gilbert’s syndrome) may also predispose certain breastfed infants to a more pronounced and prolonged BMJ. breast milk jaundice

The diagnosis of breast milk jaundice is typically made based on a combination of: Current guidelines from the American Academy of Pediatrics

It is essentially a sign that the baby is digesting breast milk properly, but their liver is still learning how to keep up with the recycling process. For mild to moderate BMJ, frequent breastfeeding (to

While the exact etiology remains under study, several theories explain why breast milk may lead to elevated bilirubin:

The cornerstone of managing BMJ is . Since BMJ is almost universally benign, no treatment is required for the majority of cases. The classic intervention used historically—temporary interruption of breastfeeding with formula substitution for 24-48 hours—is now rarely indicated. This "diagnostic interruption" leads to a rapid drop in bilirubin (by >30% in 24 hours), confirming the diagnosis, but it carries the risk of nipple confusion, decreased milk supply, and early abandonment of breastfeeding.

Neonatal jaundice, characterized by a yellowing of the skin and sclera due to elevated bilirubin levels, is one of the most common conditions encountered in newborn medicine. While often benign, it exists on a spectrum ranging from physiologic norm to pathologic emergency. Within this spectrum lies a unique and often misunderstood entity: . Distinct from the more common "breastfeeding jaundice" caused by caloric deprivation, BMJ is a prolonged, unconjugated hyperbilirubinemia in an otherwise healthy, thriving breastfed infant. This essay will explore the definition, pathophysiology, clinical presentation, differential diagnosis, and management of breast milk jaundice, arguing that while alarming to parents, it is largely a benign condition that should not discourage breastfeeding.